BridgeBio spinout to go public in SPAC deal with Helix Acquisition Corp. II
Source: SeekingAlpha
2025-02-28 10:16:57 ET
More on BridgeBio Pharma, Helix Acquisition Corp. II, etc.
- BridgeBio: Strong Start For Attruby
- BridgeBio: Post Attruby Approval, Shares Don't Look Such Good Value - Rating Downgrade
- BridgeBio Pharma Is A Buy On Dips After Attruby's FDA Approval
- BridgeBio prices offering of $500 million convertible senior notes due 2031
- BridgeBio announces offering of convertible senior notes to refinance debt
Read the full article on Seeking Alpha
For further details see:
BridgeBio spinout to go public in SPAC deal with Helix Acquisition Corp. II
Helix Acquisition Corp. II
NASDAQ: HLXB
HLXB Trading
-0.3% G/L:
$9.90 Last:
127,164 Volume:
$10.09 Open:
HLXB Latest News
August 06, 2025 07:33:00 am
Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics
